All In Biotech

Drug Trial Radar · NCT06015282

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc) in Comparison With Quadrivalent Influenza Vaccines, in Adults Aged 50 Years and Older.

Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 7,741 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,741

Actual

Start

Nov 3, 2023

Primary completion

Mar 5, 2024

Study completion Jan 30, 2025

Sponsor

Lead sponsor
SeqirusIndustry
Sponsor type
Industry
First posted
Aug 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally split between two age groups: 50-64 years; 65 years and older), who are healthy or have stable comorbidities that increase their risk of complications from influenza infection. Three lots of aQIVc will be evaluated for consistency and pooled for the comparison with the 2 control vaccines. Subjects will be randomly assigned to receive 1 of 3 lots of aQIVc, QIVr, or aQIV in a 1:1:1:2:2 ratio (for a 3:2:2 ratio for aQIVc, QIVr, and aQIV). The study will have a treatment period (Day 1 to Day 29) and a follow-up period (Day 30 up to Day 181); a subset of 770 subjects will be followed up up to Day 365.

Conditions

  • Influenza, Human

Interventions

  • Investigational aQIVcBiological

    Investigational Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

  • licensed QIVrBiological

    Recombinant Quadrivalent Influenza Vaccine (Flublok Quadrivalent/Supemtek) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.

  • licensed aQIVBiological

    Adjuvanted, egg-derived Quadrivalent Influenza Vaccine (Fluad) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immunogenicity Endpoint: Humoral immune responses of 3 lots of aQIVc compared in pairs in terms of Day 29 GMT ratio between each pair among the 3 lots, from antibody titers measured via HI assay.Time frame: Day 29
  2. Immunogenicity Endpoint: Humoral immune responses of aQIVc in comparison with QIVr and aQIV vaccines in terms of Day 29 GMT and GMT ratio of antibodies measured via HI assay.Time frame: Day 29
  3. Immunogenicity Endpoint: Humoral immune responses of aQIVc in comparison with QIVr and aQIV vaccines in terms of Day 1 to Day 29 SCR and SCR difference, from antibody titers measured via HI assay.Time frame: Day 1 and Day 29

Locations

96 sites in 8 countries. Site status is shown where the registry gives one.

  • Alliance for Multispecialty Research (AMR) Phoenix

    Tempe, Arizona

  • Baptist Health Center for Clinical Research

    Little Rock, Arkansas

  • Marvel Clinical Research

    Huntington Beach, California

  • Paradigm Clinical Research Center, LLC

    Redding, California

  • Clinical Research Consulting, Inc.

    Milford, Connecticut

  • Chase Medical Research, LLC

    Waterbury, Connecticut

  • Innovative Research of West Florida, Inc.

    Clearwater, Florida

  • USA and International Research Inc.

    Doral, Florida

  • Velocity Clinical Research, New Smyrna Beach

    Edgewater, Florida

  • Health Awareness, Inc.

    Jupiter, Florida

  • ARS - Lake Oconee

    Largo, Florida

  • Global Health Research Center

    Miami Lakes, Florida

  • Precision Clinical Research

    Sunrise, Florida

  • Global Health Research center

    Tampa, Florida

  • Velocity Clinical Research- Boise

    Meridian, Idaho

  • Great Lakes Clinical Trials, LLC Ravenswood dba Flourish Research

    Chicago, Illinois

  • Great Lakes Clinical Trials, LLC. Ravenswood dba Flourish Research

    Gurnee, Illinois

  • Velocity Clinical Research Valparaoso

    Valparaiso, Indiana

  • Velocity Clinical Research, Sioux City

    Sioux City, Iowa

  • Velocity Clinical Research, Baton Rough

    Baton Rouge, Louisiana

  • Benchmark Research

    Metairie, Louisiana

  • IMA Evaluations LLC

    Monroe, Louisiana

  • Centennial Medical Group, PC

    Columbia, Maryland

  • Velocity Clinical Research Rockville

    Rockville, Maryland

  • Velocity Clinical Research Gulfport

    Gulfport, Mississippi

  • Alliance for Multispecialty Research, LLC

    Kansas City, Missouri

  • Sundance Clinical Research

    St Louis, Missouri

  • Velocity Clinical Research, Norfolk

    Norfolk, Nebraska

  • Velocity Clinical Research, Omaha

    Omaha, Nebraska

  • Alliance for Multispecialty Research (AMR) LLC, Las Vegas

    Las Vegas, Nevada

  • Velocity Clinical Research, Binghamton

    Binghamton, New York

  • Velocity Clinical Research, Syracuse

    East Syracuse, New York

  • Velocity Clinical Research, Vestal

    New York, New York

  • M3 Wake Research, Inc

    Raleigh, North Carolina

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • Velocity Clinical Research Cincinnati

    Cincinnati, Ohio

  • Velocity Clinical Research, Cleveland

    Cleveland, Ohio

  • Velocity Clinical Research - Medford

    Medford, Oregon

  • Velocity Clinical Research-Providence

    East Greenwich, Rhode Island

  • Velocity Clinical Research, Gaffney

    Gaffney, South Carolina

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.